C3 and neuromyelitis optica: Several inhibitors targeting C1, C3, C5, and C5a have undergone development and received approval for clinical applications, although only anti-C5 therapies have received approval for CNS indications (generalized myasthenia gravis and neuromyelitis optica spectrum disorder).